Subscribe: Merck.com - Corporate News
http://www.merck.com/rss/corporate.xml
Added By: Feedage Forager Feedage Grade B rated
Language: English
Tags:
dateline city  kenilworth  language english  merck  mrk  nyse  states canada  ticker slug  ticker  united states  wire merck 
Rate this Feed
Rate this feedRate this feedRate this feedRate this feedRate this feed
Rate this feed 1 starRate this feed 2 starRate this feed 3 starRate this feed 4 starRate this feed 5 star

Comments (0)

Feed Details and Statistics Feed Statistics
Preview: Merck.com - Corporate News

Corporate News





 



Two New Trials of Merck’s KEYTRUDA® (pembrolizumab) as Monotherapy and in Combination with Chemotherapy for First-Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer to be Presented During Presidential Session at ESMO 2016

Wed, 28 Sep 2016 10:45:00 +0000

Dateline City:
KENILWORTH, N.J.

Results from KEYNOTE-024, which Studied KEYTRUDA Compared to Chemotherapy in Patients with High Levels of PD-L1 Expression, and KEYNOTE-021G, which Studied KEYTRUDA in Combination with Chemotherapy Compared to Chemotherapy Alone in Patients Regardless of PD-L1 Expression, to be Presented

Comprehensive Data from Merck’s Industry-Leading Immuno-Oncology Clinical Development Program to be Presented, with New Data in 12 Cancers

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that extensive data on KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, have been accepted for presentation at the European Society for Medical Oncology (ESMO) 2016 Congress in Copenhagen, Denmark, Oct. 7 – 11. In total, findings from 30 studies in 12 cancers from Merck’s industry-leading clinical development program for KEYTRUDA – both as monotherapy and in combination – will be presented at this year’s ESMO.

Language:
English
Contact:

Merck
Media:
Pamela Eisele, 267-305-3558
Kim Hamilton, 908-740-1863
or
Investors:
Teri Loxam, 908-740-1986
Amy Klug, 908-740-1898

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE

read more




Merck to Hold Third-Quarter 2016 Sales and Earnings Conference Call on October 25

Fri, 23 Sep 2016 12:00:00 +0000

Dateline City:
KENILWORTH, N.J.

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, will hold its third-quarter 2016 sales and earnings conference call with institutional investors and analysts at 8:00 a.m. EDT on Tuesday, Oct. 25. During the call, company executives will provide an overview of Merck’s performance for the quarter.

Language:
English
Contact:

Merck
Media:
Lainie Keller, 908-236-5036
or
Investors:
Teri Loxam, 908-740-1986
Amy Klug, 908-740-1898

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE

read more




Merck to Host Investor Teleconference to Discuss ESMO 2016 Highlights

Tue, 20 Sep 2016 12:30:00 +0000

Dateline City:
KENILWORTH, N.J.

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, will host a teleconference for investors following the presentation of data at the European Society for Medical Oncology (ESMO) 2016 Congress in Copenhagen, Denmark, Oct. 7 – 11. The call will take place on Sunday, Oct. 9 at 6:30 p.m. CEST (12:30 p.m. EDT). Company executives will provide an overview of data presented and address questions.

Language:
English
Contact:

Merck
Media:
Pamela Eisele, 267-305-3558
Kim Hamilton, 908-740-1863
or
Investors:
Teri Loxam, 908-740-1986
Amy Klug, 908-740-1898

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE

read more




Merck and Pfizer Announce Investigational Ertugliflozin Met Primary Endpoint of A1C Reduction When Added to Sitagliptin and Metformin in People with Type 2 Diabetes

Thu, 15 Sep 2016 12:31:48 +0000

Dateline City:
KENILWORTH, N.J., and NEW YORK, N.Y.

New Phase 3 Data Presented at the European Association for the Study of Diabetes Annual Meeting – Study Achieved Primary and All Key Secondary Endpoints

KENILWORTH, N.J., and NEW YORK, N.Y. -- Merck (NYSE: MRK), known as MSD outside the United States and Canada, in partnership with Pfizer Inc. (NYSE: PFE) today announced that a Phase 3 study (VERTIS SITA2) of ertugliflozin, an investigational oral SGLT2 inhibitor for the treatment of patients with type 2 diabetes, met its primary endpoint.

Language:
English

read more




Merck Publishes 2015/2016 Global Corporate Responsibility Report

Tue, 13 Sep 2016 13:00:00 +0000

Dateline City:
KENILWORTH, N.J.

Report Highlights Company’s Long-Standing Commitment to Discovering Innovative and Sustainable Solutions to the World’s Greatest Health and Development Challenges

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today issued its 2015/2016 global corporate responsibility report. The report reflects the company’s performance in the areas of Access to Health, Environmental Sustainability, Employees and Ethics & Transparency.

Language:
English
Contact:

Merck
Media:
Lainie Keller, 908-236-5036
or
Investors:
Teri Loxam, 908-740-1986
Amy Klug, 908-740-1898

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE

read more




Merck to Participate at the Morgan Stanley Global Healthcare Conference

Fri, 09 Sep 2016 12:00:00 +0000

Dateline City:
KENILWORTH, N.J.

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that Kenneth C. Frazier, chairman and chief executive officer, and Dr. Roger M. Perlmutter, president, Merck Research Laboratories, are scheduled to participate at the Morgan Stanley Global Healthcare Conference in New York on Sept. 12, 2016 at 1:05 p.m. EDT.

Language:
English
Contact:

Merck
Media:
Lainie Keller, 908-236-5036
or
Investors:
Teri Loxam, 908-740-1986
or
Amy Klug, 908-740-1898

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE

read more




FDA Accepts Supplemental Biologics License Application, Assigns Priority Review and Grants Breakthrough Therapy Designation to Merck’s KEYTRUDA® (pembrolizumab) for First-Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer

Wed, 07 Sep 2016 10:45:00 +0000

Dateline City:
KENILWORTH, N.J.

Merck Has Also Submitted a Marketing Authorization Application to the European Medicines Agency for KEYTRUDA in the Same Patient Population

Submissions Based on Data from KEYNOTE-024 Trial Showing Superior Progression-Free and Overall Survival Compared to Chemotherapy in Patients Whose Tumors Express High Levels of PD-L1

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, for the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC) whose tumors express PD-L1, with a PDUFA, or target action, date of Dec. 24, 2016.

Language:
English
Contact:

Merck
Media:
Pamela Eisele, 267-305-3558
or
Courtney Ronaldo, 908-236-1108
or
Investors:
Teri Loxam, 908-740-1986
or
Amy Klug, 908-740-1898

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE

read more




Merck Provides Update on Odanacatib Development Program

Fri, 02 Sep 2016 11:00:00 +0000

Dateline City:
KENILWORTH, N.J.

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that it is discontinuing the development of odanacatib, Merck’s investigational cathepsin K inhibitor for osteoporosis, and will not seek regulatory approval for its use.

Language:
English
Contact:

Merck
Media:
Pamela Eisele, 267-305-3558
or
Investors:
Teri Loxam, 908-740-1986

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE

read more




Results from Merck’s Phase 3 Study Evaluating ZEPATIER™ (elbasvir and grazoprevir) in Patients with Chronic Hepatitis C Receiving Treatment for Opioid Dependence Published in Annals of Internal Medicine

Mon, 08 Aug 2016 21:05:00 +0000

Dateline City:
KENILWORTH, N.J.

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the publication of results from C-EDGE CO-STAR . C-EDGE CO-STAR is a Phase 3 trial evaluating the use of ZEPATIER™ (elbasvir and grazoprevir) 50mg/100mg tablets in patients with chronic hepatitis C (HCV) genotype (GT) 1, GT4 and GT6 infection receiving opioid agonist therapy (OAT) (methadone and buprenorphine), commonly used to treat opioid addiction.

Language:
English
Contact:

Merck
Media:
Pamela Eisele, 267-305-3558
or
Sarra Herzog, 201-669-6570
or
Investor:
Teri Loxam, 908-740-1986
or
Amy Klug, 908-740-1898

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE

read more




FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Disease Progression on or After Platinum-Containing Chemotherapy

Mon, 08 Aug 2016 10:45:00 +0000

Dateline City:
KENILWORTH, N.J.

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 (programmed death receptor-1) therapy, at a fixed dose of 200 mg every three weeks, for the treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) with disease progression on or after platinum-containing chemotherapy.

Language:
English
Contact:

Merck
Media:
Pamela Eisele, 267-305-3558
or
An Phan, 908-255-6325
or
Investor:
Teri Loxam, 908-740-1898
or
Amy Klug, 908-740-1898

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE

read more




Merck Announces U.S. FDA Filing Acceptance of New Drug Application (NDA) for MK-1293, an Investigational Follow-On Biologic Insulin Glargine

Fri, 05 Aug 2016 12:00:00 +0000

Dateline City:
KENILWORTH, N.J.

Marketing Authorization Application to the European Medicines Agency Currently Under Review

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for MK-1293, an investigational follow-on biologic1 insulin glargine candidate for the treatment of people with type 1 and type 2 diabetes, which is being developed by Merck with partial funding from Samsung Bioepis.

Language:
English
Contact:

Merck
Media:
Doris Li, 908-246-5701
or
Kristen Drake, 908-236-4223
or
Investors:
Amy Klug, 908-740-1898

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE

read more




Merck’s KEYTRUDA® (pembrolizumab) Approved by the European Commission for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Express PD-L1

Tue, 02 Aug 2016 21:00:00 +0000

Dateline City:
KENILWORTH, N.J.

Approval Based on Trial Results Demonstrating Superior Overall Survival Compared to Chemotherapy in Previously-Treated Patients

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the European Commission (EC) has approved KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, at a dose of 2 mg/kg every three weeks, for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) in patients whose tumors express PD-L1 and who have received at least one prior chemotherapy regimen.

Language:
English
Contact:

Merck
Media:
Pamela Eisele, 267-305-3558
Courtney Ronaldo, 908-236-1108
or
Investors:
Teri Loxam, 908-740-1986
Amy Klug, 908-740-1898

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE

read more




Merck Announces Second-Quarter 2016 Financial Results

Fri, 29 Jul 2016 10:45:00 +0000

Dateline City:
KENILWORTH, N.J.
  • Second-Quarter 2016 Worldwide Sales Were $9.8 Billion, an Increase of 1 Percent, Including a 2 Percent Negative Impact from Foreign Exchange
  • Second-Quarter 2016 GAAP EPS Was $0.43; Second-Quarter Non-GAAP EPS Was $0.93
  • Company Updates EPS Guidance: Full-Year 2016 GAAP EPS Range to be Between $1.98 and $2.08; Full-Year 2016 Non-GAAP EPS Range of $3.67 to $3.77
  • Advanced KEYTRUDA Development Program
    • KEYTRUDA Demonstrated Superior Progression-Free Survival and Overall Survival Compared to Chemotherapy in Patients with Previously Untreated Advanced Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Expressed PD-L1 in KEYNOTE-024 Study
    • Merck Received Positive Opinion from Committee for Medicinal Products for Human Use of the European Medicines Agency for KEYTRUDA for the Treatment of Previously Treated Advanced NSCLC in Patients Whose Tumors Express PD-L1

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced financial results for the second quarter of 2016.

Language:
English
Contact:

Merck
Media:
Lainie Keller, 908-236-5036
or
Investors:
Teri Loxam, 908-740-1986
Justin Holko, 908-740-1879

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE

read more




Merck Announces Fourth-Quarter 2016 Dividend

Tue, 26 Jul 2016 16:50:00 +0000

Dateline City:
KENILWORTH, N.J.

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the Board of Directors has declared a quarterly dividend of $0.46 per share of the company’s common stock for the fourth quarter of 2016. Payment will be made on Oct. 7, 2016 to shareholders of record at the close of business on Sept. 15, 2016.

About Merck

Language:
English
Contact:

Merck
Media:
Lainie Keller, 908-236-5036
or
Investors:
Justin Holko, 908-740-1879

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE

read more




Merck Receives Breakthrough Therapy Designation from FDA and PRIME Status from EMA for Investigational Ebola Zaire Vaccine (V920)

Mon, 25 Jul 2016 12:00:00 +0000

Dateline City:
KENILWORTH, N.J.

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced two regulatory milestones for the company’s investigational vaccine for Ebola Zaire, V920 (rVSV∆G-ZEBOV-GP, live attenuated): the U.S. Food and Drug Administration (FDA) has granted the vaccine candidate Breakthrough Therapy Designation, and the European Medicines Agency (EMA) has granted PRIME (PRIority MEdicines) status.

Language:
English
Contact:

Merck
Media:
Pamela Eisele, 267-305-3558
Skip Irvine, 215-652-6059
or
Investors:
Teri Loxam, 908-740-1986
Justin Holko, 908-423-5088

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE

read more




Data for Merck's Investigational Once-Daily Formulation of ISENTRESS® (raltegravir) Show That at Week 48, a Regimen Containing the Once-Daily Dosing Formulation...

Fri, 22 Jul 2016 11:00:00 +0000

Dateline City:
KENILWORTH, N.J.

Resulted in Non-Inferior Efficacy and Safety to a Regimen Containing the Approved Twice-Daily Formulation

EMA Accepts File Application, Plans Underway to Submit for Licensure to FDA This Year

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced efficacy and safety data in previously untreated adults with HIV-1 infection for the company’s investigational once-daily formulation of ISENTRESS® (raltegravir), known as raltegravir 600 mg (to be given as 2 x 600 mg), from the ongoing Phase 3 pivotal trial called ONCEMRK.

Language:
English
Contact:

Merck
Media:
Pam Eisele, 267-305-3558
Carmen de Gourville, 267-305-4195
or
Investors:
Teri Loxam, 908-740-1986
Amy Klug, 908-740-1898

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE

read more




Merck Animal Health Receives FDA Approval of BRAVECTO® (fluralaner topical solution) for Cats and Dogs

Thu, 21 Jul 2016 21:00:00 +0000

Dateline City:
MADISON, N.J.

Topical Treatment for Fleas and Ticks Effective for up to 12 Weeks

MADISON, N.J.--(BUSINESS WIRE)--Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, today announced the U.S. Food and Drug Administration’s approval of BRAVECTO® (fluralaner topical solution) for both cats and dogs, a topical treatment for fleas and ticks effective for up to 12 weeks1,2 following a single dose.

Language:
English
Contact:

Merck Animal Health
Media:
Kelly Goss, 913-558-6452
kelly.goss@merck.com
or
Pamela Eisele, 267-305-3558
pamela.eisele@merck.com
or
Investor Relations:
Amy Klug, 908-740-1898
amy.klug@merck.com

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE

read more




Merck Provides Regulatory Update on Biologics Licensing Application for Investigational Agent Bezlotoxumab

Thu, 21 Jul 2016 20:30:00 +0000

Dateline City:
KENILWORTH, N.J.

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today said that the U.S. Food and Drug Administration (FDA) has requested the submission of new data and analyses from the MODIFY I and MODIFY II clinical trials previously submitted to the pending Biologics Licensing Application (BLA) for bezlotoxumab, an investigational agent for prevention of Clostridium difficile (C. difficile) infection recurrence.

Language:
English
Contact:

Merck
Media:
Pamela Eisele, 267-305-3558
Robert Consalvo, 908-236-1127
or
Investors:
Teri Loxam, 908-740-1986
Amy Klug, 908-740-1898

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE

read more




Merck Animal Health Announces Agreement to Acquire Controlling Interest In Brazilian Animal Health Company Vallée S.A.

Fri, 01 Jul 2016 16:05:00 +0000

Dateline City:
MADISON, N.J.

Manufacturer Offers Substantial Portfolio of Animal Vaccines in Latin America

MADISON, N.J.--(BUSINESS WIRE)--Merck Animal Health (known as MSD Animal Health outside the United States and Canada) today announced it has executed an agreement to acquire a controlling interest in Vallée S.A., a leading privately-held producer of animal health products in Brazil.

Language:
English
Contact:

Merck Animal Health
Media:
Amy Firsching, +1-973-937-5453
amy.firsching@merck.com
or
Pam Eisele, + 1-267-305-3558
pamela.eisele@merck.com
or
Investors:
Amy Klug, +1-908-740-1898
Amy.klug@merck.com

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE

read more




Merck and Premier Inc. Collaborate to Prevent Fractures for Osteoporosis Patients

Thu, 30 Jun 2016 12:30:58 +0000

Dateline City:
KENILWORTH, N.J. and CHARLOTTE, N.C.

Companies working alongside providers to develop solutions to serious public health needs

KENILWORTH, N.J. and CHARLOTTE, N.C. -- Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Premier Inc. (NASDAQ: PINC), a leading healthcare improvement company, have agreed to collaborate on the co-development of solutions to help improve population health. Initially, the companies will focus on reducing fracture rates for at-risk osteoporosis patients.

Language:
English

read more




Merck and Moderna Announce Strategic Collaboration to Advance Novel mRNA-Based Personalized Cancer Vaccines with KEYTRUDA® (pembrolizumab) for the Treatment of Multiple Types of Cancer

Wed, 29 Jun 2016 11:00:00 +0000

Dateline City:
KENILWORTH, N.J. & CAMBRIDGE, Mass.

Collaboration Combines Merck’s Leadership in Immuno-Oncology with Moderna’s Pioneering mRNA Vaccine Technology and Rapid Cycle Time, Small-Batch GMP Manufacturing Capabilities

KENILWORTH, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Moderna Therapeutics today announced a strategic collaboration and license agreement to develop and commercialize novel messenger RNA (mRNA)-based personalized cancer vaccines.

Language:
English
Contact:

Merck
Media:
Pamela Eisele, 267-305-3558
or
Courtney Ronaldo, 908-236-1108
or
Investors:
Teri Loxam, 908-740-1986
or
Justin Holko, 908-740-1879
or
Moderna
Media:
Liz Melone, 617-256-6622
or
Investors:
Maren Winnick, 617-674-5297

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE

read more




Merck Receives CHMP Positive Opinion for KEYTRUDA® (pembrolizumab) for the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)

Mon, 27 Jun 2016 10:00:00 +0000

Dateline City:
KENILWORTH, N.J.

Opinion Based on Data from KEYNOTE-010, Which Showed Superior Overall Survival Compared to Chemotherapy in Previously-Treated Patients Whose Tumors Express PD-L1

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) in adults whose tumors express PD-L1 and who have received at least one prior chemotherapy regimen.

Language:
English
Contact:

Merck
Media:
Pamela Eisele, 267-305-3558
Courtney Ronaldo, 908-236-1108
or
Investor:
Teri Loxam, 908-740-1986
Justin Holko, 908-740-1879

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE

read more




Merck to Hold Second-Quarter 2016 Sales and Earnings Conference Call on July 29

Fri, 24 Jun 2016 12:00:00 +0000

Dateline City:
KENILWORTH, N.J.

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, will hold its second-quarter 2016 sales and earnings conference call with institutional investors and analysts at 8:00 a.m. EDT on Friday, July 29. During the call, company executives will provide an overview of Merck’s performance for the quarter.

Language:
English
Contact:

Merck
Media:
Lainie Keller, 908-236-5036
or
Investors:
Teri Loxam, 908-740-1986
Justin Holko, 908-740-1879

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE

read more




Results of Phase 2 Study of Merck’s Investigational Beta-Lactamase Inhibitor Relebactam in Combination with Imipenem/Cilastatin Presented at ASM Microbe

Mon, 20 Jun 2016 16:30:00 +0000

Dateline City:
KENILWORTH, N.J.

Pivotal Phase 3 Studies Ongoing in Treatment of Serious Bacterial Infections

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that a Phase 2 study of relebactam, the company’s investigational beta-lactamase inhibitor, in combination with imipenem/cilastatin (an approved carbapenem antibiotic), in patients with complicated urinary tract infections, met its primary endpoint.

Language:
English
Contact:

Merck
Media:
Pamela Eisele, (267) 305-3558
or
Robert Consalvo, (908) 295-0928
or
Investor:
Teri Loxam, (908) 740-1986
or
Amy Klug, (908) 740-1898

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE

read more




Systematic Review of 58 Publications of Real-World Use of GARDASIL® Presented at EUROGIN Congress

Thu, 16 Jun 2016 12:00:00 +0000

Dateline City:
KENILWORTH, N.J.

Studies Published over the Last 10 Years Report Reductions in Cervical Pre-cancers and Other HPV-related Diseases

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside of the United States and Canada, announced today that in a systematic review conducted of the global impact and effectiveness of GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant], substantial reductions were observed in HPV 6/11/16/18-related infection, genital warts, Pap abnormalities and cervical pre-cancers.

Language:
English
Contact:

Merck
Media:
Pamela Eisele, 267-305-3558
Deb Wambold, 215-652-2913
or
Investors:
Teri Loxam, 908-740-1986
Justin Holko, 908-740-1879

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE

read more